Which of the following adverse reactions is possible with a bisphosphonate such as ibandronate (Boniva)?

Rationale: A. Bisphosphonates like ibandronate are known to cause significant localized irritation to the upper gastrointestinal mucosa. If the medication remains in contact with the esophageal lining, it can lead to severe erosive esophagitis and the formation of esophageal ulcers. Patients are strictly instructed to remain upright for at least 30 to 60 minutes after ingestion to prevent the reflux of this caustic agent. B. Heart failure is not a recognized adverse effect of the bisphosphonate class of medications used for osteoporosis. These drugs primarily target bone metabolism by inhibiting osteoclast-mediated bone resorption rather than affecting myocardial contractility or fluid volume. While some older studies suggested a minor link to atrial fibrillation, there is no established causal relationship between ibandronate and the development of congestive heart failure. C. Prolonged QTc interval is a cardiac conduction abnormality typically associated with certain antiarrhythmics, antipsychotics, or electrolyte imbalances. Bisphosphonates do not possess the pharmacological properties required to alter the repolarization phase of the cardiac action potential. Monitoring of the electrocardiogram is not a standard requirement for patients initiated on ibandronate therapy as it does not carry a risk for Torsades de Pointes. D. This choice is incorrect because only the gastrointestinal risks are scientifically validated complications of bisphosphonate therapy. Neither heart failure nor QTc prolongation are clinical markers associated with this drug class. Medical professionals must focus on the correct administration techniques to mitigate the very real risk of esophageal damage rather than monitoring for unrelated cardiac pathologies.